CSCésar Samanez

César Samanez

*This is an algorithmically generated author record based on publicly available information.

César Samanez has a total of 57 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Treatment patterns and clinical outcomes in acute myeloid leukemia patients who are not eligible for intensive induction chemotherapy: A real-world study from Latin-America

    by Kenny Mauricio Gálvez-Cárdenas, Leonardo José Enciso-Olivera, César Augusto Samanez-Figari, Shirley Quintana-Truyenque, Benito Arturo Castillo-Ríos, Guillermo Enrique Quintero-Vega, Elizabeth Arrieta-López, Alexis Javier Pinto-Gómez, Sandra Aruachan-Vesga, María Isabel Durán-Sánchez, et al.

    Introduction. There is a knowledge gap concerning patients with acute myeloid leukemia (AML) who are not eligible for intensive induction chemotherapy; this, together with a recent increase in the incidence in Latin America, encloses a need. Through real-world evidence, we describe and compare the results of the different treatment strategies within this context. Methodology. This is a longitudinal, descriptive, retrospective study of a cohort of Latin American patients with AML not eligible for intensive induction chemotherapy, treated with low-intensity chemotherapy or with the best supportive care alone between January 1, 2015, to December 31, 2018. Results. Of a total of 125 patients (median age 74.8 years), the majority received low-intensity chemotherapy (78.4%). The median time in months of overall survival (9.2), progression-free survival (4.8), and time to treatment failure (3.8) were longer in patients receiving hypomethylating agents. Additionally, better results were observed with low-intensity chemotherapy (complete response 11.2% and stable disease 17.3%) compared to the best supportive care alone. Conclusion. We deliver a real-world standpoint of Latin American patients with AML who are not eligible for intensive induction chemotherapy. Our findings pave the first steps of the way to describe, understand, and support informed decision-making processes in our region.


  • Open Access

    Treatment and Survival Outcomes of Waldenstrom Macroglobulinemia in Latin American Patients: A Multinational Retrospective Cohort Study

    by Eloísa Riva, Patricio José Duarte, Bryan Valcárcel, Guillermina Remaggi, Ivan Murrieta, Ariel Corzo, Daniel del Carpio, Camila Peña, Jule Vásquez, Virginia Bove, et al.

    PURPOSE: Waldenstrom Macroglobulinemia (WM) is a rare lymphoma with distinct clinical features, and data from Latin American patients are lacking. Therefore, we aim to investigate the clinical, therapy, and outcome patterns of WM in Latin America. METHODS: We retrospectively analyzed patients with WM diagnosed between 1991 and 2019 from 24 centers in seven Latin American countries. The study outcomes were overall survival (OS) and progression-free survival (PFS). RESULTS: We identified 159 cases (median age 67 years, male 62%). Most patients (95%) were symptomatic at diagnosis. The International Prognostic Scoring System for WM (IPSSWM) at diagnosis was available in 141 (89%) patients (high-risk 40%, intermediate-risk 37%, and low-risk 23%). Twenty-seven (17%) patients were tested for MYD88L265P, with 89% (n = 24 of 27) carrying the mutation. First-line and second-line therapies were administered to 142 (89%) and 53 (33%) patients, respectively. Chemoimmunotherapy was the most commonly used first-line (66%) and second-line (45%) approach; only 18 (11%) patients received ibrutinib. With a median follow-up of 69 months, the 5-year OS rate was 81%. In treated patients, the 5-year OS and PFS rates were 78% and 59%, respectively. High-risk IPSSWM at treatment initiation was an independent risk factor for OS (adjusted hazard ratio: 4.73, 95% CI, 1.67 to 13.41, P = .003) and PFS (adjusted hazard ratio: 2.43, 95% CI, 1.31 to 4.50, P = .005). CONCLUSION: In Latin America, the management of WM is heterogeneous, with limited access to molecular testing and novel agents. However, outcomes were similar to those reported internationally. We validated the IPSSWM score as a prognostic factor for OS and PFS. There is an unmet need to improve access to recommended diagnostic approaches and therapies in Latin America.


  • Open Access

    Epidemiology and Risk Factors for the Development of Infectious Complications in Newly Diagnosed Multiple Myeloma: A Multicenter Prospective Cohort Study in Latin America

    by Virginia Bove, Eloísa Riva, Jule Vásquez, Camila Peña, Cristian Seehaus, César Samanez, Justina Bustos, Marcos Hernández, Julio Fernández, Oliday Ríos, et al.

    PURPOSE: Infections are a significant cause of morbidity and mortality in patients with multiple myeloma (MM). In Latin America, data on infectious complications in this patient population are lacking. METHODS: We conducted a prospective cohort study of patients with newly diagnosed MM (NDMM) in seven Latin American countries between June 2019 and May 2020. Patients with active disease, on active therapy, and with a follow-up of 6 months from the time of diagnosis were included. Our primary end point was the number of infectious events that required hospitalization for ≥ 24 hours. RESULTS: Of 248 patients with NDMM, 89 (35.9%) had infectious complications (113 infectious events), the majority (67.3%) within the first 3 months from diagnosis. The most common sites of infection were respiratory (38%) and urinary tract (31%). The microbial agent was identified in 57.5% of patients with gram-negative bacteria (73.5%) as the most common pathogen. Viral infections were infrequent, and no patients with fungal infection were reported. In the multivariable analysis, diabetes mellitus (odds ratio [OR], 2.71; 95% CI, 1.23 to 6.00; P = .014), creatinine ≥ 2 mg/dL (OR, 4.87; 95% CI, 2.29 to 10.35; P < .001), no use of trimethoprim-sulfamethoxazole prophylaxis (OR, 6.66; 95% CI, 3.43 to 12.92; P < .001), and treatment with immunomodulatory drugs (OR, 3.02; 95% CI, 1.24 to 6.29; P = .003) were independent factors associated with bacterial infections. At 6 months, 21 patients (8.5%) had died, 47.6% related to infectious complications. CONCLUSION: Bacterial infections are a substantial cause of hospital admissions and early death in patients with NDMM. Antibiotic prophylaxis should be considered to reduce infectious complications in patients with MM.


  • Open Access

    Manejo multidisciplinario de la Neutropenia Febril: Consenso Institucional. Lima, Perú.

    by Cindy Alcarraz, Fradis Gil-Olivares, Claudia Banda-Flores, Connie Rabanal-Carretero, Carlos Seas-Ramos, Theresa Ochoa-Woodell, Juan García-León, Tatiana Saldarriaga-Valiente, Antonio Carrazco-Yalán, Shirley Quintana-Truyenque, et al.

    Introducción: Brindar recomendaciones basadas en la mejor evidencia científica disponible para el manejo multidisciplinario de la neutropenia febril. El desarrollo abarco las etapas: aprobación de la conformación del Grupo Elaborador (GE); búsqueda de GPC; análisis y síntesis de la evidencia que llevó al establecimiento de la recomendación de las GPC seleccionadas, diseño del documento consenso, revisión interna. Todas las fases fueron llevadas a cabo mediante reuniones de panel a través del uso de plataformas virtuales durante 03 meses. Se utilizó el sistema “GRADE” para establecer la fuerza y dirección de las recomendaciones. Las recomendaciones abarcan la prevención, el diagnóstico y tratamiento de la neutropenia febril en pacientes oncohematológicos. Se formularon 28 recomendaciones. Los temas abordados han sido relacionados a: correcta evaluación; diagnóstico oportuno, tratamiento antibiótico adecuado, vacunación contra influenza y neumococo, administración de factor estimulante de colonias y manejo especial en pacientes pediátricos para diagnóstico, tratamiento.